| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by first author.
Page 3: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 601 | 6 | 24 | 1543 2002 PHARMACEUTICAL RESEARCH 19(1):13-19 Goosen C; Laing TJ; du Plessis J; Goosen TC; Flynn GL Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs | 4 | 4 |
| 602 | 3 | 21 | 1544 2002 PHARMACEUTICAL RESEARCH 19(4):434-439 Goosen C; Laing TJ; du Plessis J; Goosen TC; Lu GW; Flynn GL Percutaneous delivery of thalidomide and its N-alkyl analogs | 3 | 4 |
| 603 | 10 | 18 | 1545 2002 PHARMACEUTICAL RESEARCH 19(8):1232-1235 Goosen C; Laing TJ; du Plessis J; Goosen TC; Rao TB; Flynn GL Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs | 3 | 3 |
| 604 | 0 | 0 | 15 1981 FEDERATION PROCEEDINGS 40(3):668-668 GORDON GB; SPIELBERG SP; BLAKE DA; BALASUBRAMANIAN V THALIDOMIDE TERATOGENESIS - EVIDENCE FOR A TOXIC ARENE OXIDE METABOLITE | 0 | 0 |
| 605 | 0 | 24 | 26 1981 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES 78(4):2545-2548 GORDON GB; SPIELBERG SP; BLAKE DA; BALASUBRAMANIAN V THALIDOMIDE TERATOGENESIS - EVIDENCE FOR A TOXIC ARENE OXIDE METABOLITE | 48 | 89 |
| 606 | 66 | 77 | 1814 2003 POSTGRADUATE MEDICAL JOURNAL 79(929):127-132 Gordon JN; Goggin PM Thalidomide and its derivatives: emerging from the wilderness | 0 | 3 |
| 607 | 0 | 0 | 1905 2004 GASTROENTEROLOGY 126(4):A396-A397 Gordon JN; Trebble TM; Johns T; Ellis RD; Duncan HD; Goggin PM Thalidomide in the treatment of cancer cachexia: A randomised placebo controlled trial | 0 | 0 |
| 608 | 0 | 0 | 1705 2003 CLINICAL PHARMACOLOGY & THERAPEUTICS 73(2):P55-P55 Gordon SM; Wahl SM; Picco C; Dionne RA Safety and tolerability and absorption of topical thalidomide. | 0 | 0 |
| 609 | 2 | 5 | 692 1998 CLINICAL INFECTIOUS DISEASES 26(1):184-185 Gori A; Franzetti F; Marchetti G; Rossi C; Fusi ML; Ruzzante S; Clerici M Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection | 5 | 7 |
| 610 | 5 | 5 | 872 2000 AIDS 14(12):1859-1861 Gori A; Rossi MC; Marchetti G; Trabattoni D; Molteni C; Cogliati M; Bandera A; Clerici M; Franzetti F Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease | 5 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 611 | 8 | 8 | 1010 2000 JOURNAL OF INFECTIOUS DISEASES 182(2):639-639 Gori A; Rossi MC; Trabattoni D; Marchetti G; Fusi ML; Molteni C; Clerici M; Franzetti F Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection | 6 | 7 |
| 612 | 3 | 3 | 285 1990 LANCET 335(8701):1343-1343 GORIN I; VILETTE B; GEHANNO P; ESCANDE JP THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 21 | 31 |
| 613 | 2 | 8 | 1041 2000 ONCOLOGY-NEW YORK 14(12):29-32 Govindarajan R Irinotecan and thalidomide in metastatic colorectal cancer | 7 | 12 |
| 614 | 4 | 8 | 1255 2001 ONCOLOGY-NEW YORK 15(7):877-878 Govindarajan R Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
| 615 | 4 | 17 | 1539 2002 ONCOLOGY-NEW YORK 16(4):23-26 Govindarajan R Irinoteean/Thalidomide in metastatic colorectal cancer | 5 | 6 |
| 616 | 2 | 5 | 1017 2000 LANCET 356(9229):566-567 Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M Effect of thalidomide on gastrointestinal toxic effects of irinotecan | 21 | 30 |
| 617 | 3 | 5 | 740 1998 REVUE DE MEDECINE INTERNE 19(3):208-209 Grasland A; Pouchot J; Chaumaiziere D; Aitken G; Vinceneux P Effectiveness of thalidomide in cutaneous sarcoidosis | 3 | 4 |
| 618 | 1 | 1 | 250 1989 ANAESTHESIA 44(1):69-69 GRAYLING GW; YOUNG PN ANESTHESIA AND THALIDOMIDE-RELATED ABNORMALITIES | 0 | 0 |
| 619 | 11 | 63 | 1830 2004 ACTA NEUROBIOLOGIAE EXPERIMENTALIS 64(1):1-9 Greig NH; Giordano T; Zhu XX; Yu QS; Perry TA; Holloway HW; Brossi A; Rogers JT; Sambamurti K; Lahiri DK Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases | 0 | 0 |
| 620 | 3 | 18 | 156 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 12(1):85-90 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 25 | 42 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 621 | 1 | 3 | 159 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT - REPLY | 1 | 1 |
| 622 | 13 | 39 | 262 1989 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 20(6):1060-1063 GRINSPAN D; BLANCO GF; AGUERO S TREATMENT OF APHTHAE WITH THALIDOMIDE | 9 | 24 |
| 623 | 0 | 0 | 1108 2001 BLOOD 98(11):163A-163A Grosbois B; Bellissant E; Moreau P; Attal M; Zerbib R Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. | 0 | 5 |
| 624 | 0 | 0 | 1122 2001 BLOOD 98(11):308B-308B Grosbois B; Bellissant E; Muret E; Voillat L; Zerbib R Measurement of seric thalidomide (Thal) level in patients treated for advanced multiple myeloma (MM). | 0 | 2 |
| 625 | 13 | 18 | 1265 2001 REVUE DE MEDECINE INTERNE 22(1):5-7 Grosbois B; Duguet C Thalidomide: the revival | 2 | 4 |
| 626 | 22 | 61 | 117 1984 INTERNATIONAL JOURNAL OF DERMATOLOGY 23(9):598-602 GROSSHANS E; ILLY G THALIDOMIDE THERAPY FOR INFLAMMATORY DERMATOSES | 55 | 62 |
| 627 | 2 | 2 | 151 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(9):616-616 GROSSHANS EM DISCOID LUPUS-ERYTHEMATOSUS - THALIDOMIDE OR VITAMIN-E | 0 | 0 |
| 628 | 0 | 0 | 1346 2002 BLOOD 100(11):346B-346B Grossi A; Gavazzi S; Biscardi M; Balestri F; Bonsi L; Bagnara G; Pierdomenico L; Mazzucconi F Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis. | 0 | 1 |
| 629 | 0 | 0 | 1644 2003 BLOOD 102(11):489B-490B Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma. | 0 | 0 |
| 630 | 0 | 0 | 1852 2004 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 10(2):73-73 Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 631 | 4 | 6 | 1296 2002 ANNALS OF ONCOLOGY 13(10):1636-1640 Grover JK; Uppal G; Raina V The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma | 3 | 4 |
| 632 | 92 | 148 | 1028 2000 NATIONAL MEDICAL JOURNAL OF INDIA 13(3):132-141 Grover JK; Vats V; Gopalakrishna R; Ramam M Thalidomide: A re-look | 2 | 3 |
| 633 | 13 | 49 | 958 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 121(3):472-479 Guckian M; Dransfield I; Hay P; Dalgleish AG Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro | 4 | 6 |
| 634 | 0 | 0 | 530 1996 IMMUNOLOGY 89:E51-E51 Guckian M; Marriott JB; Cookson S; Westby M; Dalgleish G Thalidomide analog 3052 reduces NK activity and PHA-induced proliferation in vitro. | 0 | 0 |
| 635 | 1 | 3 | 850 1999 NATURE MEDICINE 5(8):853-853 Guenzler V Mechanisms of thalidomide teratogenicity | 2 | 3 |
| 636 | 8 | 14 | 461 1995 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 233(2):90-93 GUEXCROSIER Y; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE AND SUPIDIMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 5 | 6 |
| 637 | 0 | 0 | 1626 2003 BLOOD 102(11):383B-383B Guglielmelli T; Capella S; Mattioli G; Guerrasio A; Saglio G Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma. | 0 | 0 |
| 638 | 7 | 19 | 435 1995 ARCHIVES OF DERMATOLOGY 131(9):1032-1035 GUILLAUME JC; MOULIN G; DIENG MT; POLI F; MOREL P; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DANIEL F; VAILLANT L; BERNARD P; BOUILLIE MC; BOURNERIAS I; DENOEUX JP; LAMBERT D; LEONARD F; CHAUMEIL JC; REVUZ J CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN JESSNERS LYMPHOCYTIC INFILTRATION OF THE SKIN | 12 | 17 |
| 639 | 2 | 19 | 729 1998 METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 20(9):739-742 Guinan P; Shaw M; Mirochnik Y; Slobodskoy L; Ray V; Rubenstein M Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model | 2 | 5 |
| 640 | 13 | 27 | 1286 2002 AMERICAN HEART JOURNAL 144(5):847-850 Gullestad L; Semb AG; Holt E; Skardal R; Ueland T; Yndestad A; Froland SS; Aukrust P Effect of thalidomide in patients with chronic heart failure | 1 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 641 | 21 | 64 | 263 1989 MEDICAL HYPOTHESES 30(2):105-109 GUNZLER V THALIDOMIDE - A THERAPY FOR THE IMMUNOLOGICAL CONSEQUENCES OF HIV INFECTION | 4 | 6 |
| 642 | 0 | 0 | 320 1992 DRUG SAFETY 7(2):116-134 GUNZLER V THALIDOMIDE IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) PATIENTS - A REVIEW OF SAFETY CONSIDERATIONS | 59 | 75 |
| 643 | 2 | 36 | 178 1986 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 36-2(7):1138-1141 GUNZLER V; HANAUSKEABEL HM; TSCHANK G; SCHULTEWISSERMANN H IMMUNOLOGICAL EFFECTS OF THALIDOMIDE - INACTIVITY OF THE DRUG AND SEVERAL OF ITS HYDROLYSIS PRODUCTS IN MONONUCLEOCYTE PROLIFERATION TESTS | 0 | 10 |
| 644 | 0 | 0 | 1029 2000 NEUROLOGY 54(7):A12-A13 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips P A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1) | 0 | 0 |
| 645 | 6 | 10 | 1801 2003 NEUROLOGY 60(1):130-132 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips PC Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1 | 1 | 4 |
| 646 | 0 | 0 | 1724 2003 GASTROENTEROLOGY 124(4):A525-A525 Gupta P; Andrew H; Kirschner BS Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab | 0 | 0 |
| 647 | 4 | 4 | 949 2000 BRITISH JOURNAL OF HAEMATOLOGY 110(3):754-754 Gutheil J; Finucane D Thalidomide therapy in refractory solid tumour patients | 10 | 13 |
| 648 | 2 | 24 | 108 1984 ARTHRITIS AND RHEUMATISM 27(10):1118-1121 GUTIERREZRODRIGUEZ O THALIDOMIDE - A PROMISING NEW TREATMENT FOR RHEUMATOID-ARTHRITIS | 47 | 56 |
| 649 | 4 | 5 | 226 1988 ARTHRITIS AND RHEUMATISM 31(1):145-146 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O THALIDOMIDE-INDUCED NEUROPATHY IN RHEUMATOID-ARTHRITIS PATIENTS | 2 | 4 |
| 650 | 7 | 27 | 261 1989 JOURNAL OF RHEUMATOLOGY 16(2):158-163 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O TREATMENT OF REFRACTORY RHEUMATOID-ARTHRITIS - THE THALIDOMIDE EXPERIENCE | 55 | 72 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 651 | 3 | 25 | 500 1996 ANTICANCER RESEARCH 16(6B):3673-3677 Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo | 16 | 23 |
| 652 | 14 | 32 | 1090 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(4):1059-1065 Gutschow M; Hecker T; Thiele A; Hauschildt S; Eger K Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro | 3 | 8 |
| 653 | 0 | 0 | 1773 2003 LANCET ONCOLOGY 4(12):713-713 Habeck M Australia approves thalidomide | 0 | 0 |
| 654 | 7 | 12 | 1825 2003 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 16(2):123-129 Hadgraft J; Goosen C; du Plessis J; Flynn G Predicting the dermal absorption of thalidomide and its derivatives | 0 | 0 |
| 655 | 0 | 3 | 228 1988 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 26(5):P623-P623 HAGUE D; SMITH RL ENIGMATIC PROPERTIES OF (+/-)-THALIDOMIDE - AN EXAMPLE OF A STABLE RACEMIC COMPOUND | 6 | 7 |
| 656 | 5 | 11 | 848 1999 NATURE MEDICINE 5(5):489-490 Hales BF Thalidomide on the comeback trail | 30 | 32 |
| 657 | 0 | 0 | 214 1987 TERATOLOGY 35(2):A73-A73 HALES BF; JAIN R SPECIES-DIFFERENCES IN THE EFFECTS OF DRUG-METABOLIZING-ENZYMES ON THE TERATOGENICITY OF THALIDOMIDE IN RAT EMBRYO CULTURES | 0 | 1 |
| 658 | 10 | 14 | 1763 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(4):548-552 Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV Dermatologic side effects of thalidomide in patients with multiple myeloma | 3 | 4 |
| 659 | 0 | 0 | 577 1997 ARTHRITIS AND RHEUMATISM 40(9):210-210 Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Randomised and placebo controlled trial of two different doses of thalidomide in Behcet's syndrome | 0 | 0 |
| 660 | 11 | 25 | 660 1998 ANNALS OF INTERNAL MEDICINE 128(6):443-+ Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial | 67 | 127 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 661 | 1 | 7 | 271 1990 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 8(4):427-427 HAMZA M BEHCETS-DISEASE, PALMOPLANTAR PUSTULOSIS AND HLA-B27 TREATMENT WITH THALIDOMIDE | 8 | 9 |
| 662 | 0 | 5 | 50 1982 NOUVELLE PRESSE MEDICALE 11(14):1080-1081 HAMZA M; CHAFFAI M; BENAYED H TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 9 | 15 |
| 663 | 0 | 0 | 206 1987 CLINICAL RHEUMATOLOGY 6(4):608-609 HAMZA M; HAMZAOUI K; AYED K; ELEUCH M; ZRIBI A THALIDOMIDE AND CELL-MEDIATED IMMUNITY IN BEHCETS-DISEASE | 0 | 2 |
| 664 | 0 | 0 | 181 1986 CLINICAL RHEUMATOLOGY 5(3):365-371 HAMZA MH TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 21 | 40 |
| 665 | 0 | 0 | 1046 2000 PEDIATRIC RESEARCH 47(4):264A-264A Hanekom W; Ganiso B; Appolis P; Hughes J; Allin R; Goddard E; Haslett P; Hussey G; Kaplan G Safety and immune effects of thalidomide in HIV-infected children | 0 | 0 |
| 666 | 10 | 15 | 1229 2001 JOURNAL OF INFECTIOUS DISEASES 184(9):1192-1196 Hanekom WA; Hughes J; Haslett PAJ; Apolles P; Ganiso V; Allin R; Goddard E; Hussey GD; Kaplan G The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children | 3 | 3 |
| 667 | 8 | 40 | 862 1999 REPRODUCTIVE TOXICOLOGY 13(6):547-554 Hansen JM; Carney EW; Harris C Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro | 6 | 11 |
| 668 | 0 | 0 | 1191 2001 FREE RADICAL BIOLOGY AND MEDICINE 31:S54-S54 Hansen JM; Gong SG; Harris C Thalidomide (TD) depletes glutathione and alters gene expression in the developing limb. | 0 | 0 |
| 669 | 6 | 38 | 1437 2002 DEVELOPMENTAL DYNAMICS 225(2):186-194 Hansen JM; Gong SG; Philbert M; Harris C Misregulation of gene expression in the redox-sensitive NF-kappa B-dependent limb outgrowth pathway by thalidomide | 1 | 3 |
| 670 | 19 | 91 | 1845 2004 ANTIOXIDANTS & REDOX SIGNALING 6(1):1-14 Hansen JM; Harris C A novel hypothesis for thalidomide-induced limb teratogenesis: Redox misregulation of the NF-kappa B pathway | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 671 | 10 | 40 | 1507 2002 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 300(3):768-776 Hansen JM; Harris KK; Philbert MA; Harris C Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb | 2 | 5 |
| 672 | 10 | 15 | 713 1998 JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 21(14):2151-2163 Haque A; Stewart JT Determination of racemic thalidomide in human plasma by use of an avidin column and solid phase extraction | 3 | 5 |
| 673 | 0 | 0 | 1860 2004 BONE MARROW TRANSPLANTATION 33:S156-S157 Hardan I; Kneller A; Shimoni A; Berkowicz M; Avigdor A; Yeshurun M; Raanani P; Davidowich Y; Shemtov N; Ben Bassat I; Nagler A Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation | 0 | 0 |
| 674 | 0 | 0 | 360 1993 CLINICAL RESEARCH 41(2):A496-A496 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 1 | 1 |
| 675 | 0 | 0 | 366 1993 JOURNAL OF INVESTIGATIVE DERMATOLOGY 100(4):492-492 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND DRUG METABOLIC POLYMORPHISM | 0 | 0 |
| 676 | 9 | 31 | 455 1995 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 49(1-2):1-6 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND GENETIC-DIFFERENCES IN DRUG-METABOLISM | 20 | 23 |
| 677 | 5 | 6 | 1681 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):160-161 Harris E; Behrens J; Samson D; Rahemtulla A; Russell NH; Byrne JL Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia | 2 | 3 |
| 678 | 1 | 2 | 503 1996 ARCHIVES OF DISEASE IN CHILDHOOD 75(1):90-90 Harry TC Thalidomide treatment of mucosal ulcerations in HIV infection | 0 | 0 |
| 679 | 22 | 80 | 694 1998 CURRENT MEDICINAL CHEMISTRY 5(3):163-178 Hashimoto Y Novel biological response modifiers derived from thalidomide | 16 | 38 |
| 680 | 26 | 91 | 1313 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479 Hashimoto Y Structural development of biological response modifiers based on thalidomide | 8 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 681 | 5 | 27 | 1690 2003 CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
| 682 | 8 | 28 | 1894 2004 DRUGS OF THE FUTURE 29(4):383-391 Hashimoto Y; Tanatani A; Nagasawa K; Miyachi H Thalidomide as a multitarget drug and its application as a template for drug design | 0 | 0 |
| 683 | 7 | 25 | 568 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(12):1047-1054 Haslett P; Hempstead M; Seidman C; Diakun J; Vasquez D; Freedman VH; Kaplan G The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus | 36 | 57 |
| 684 | 11 | 25 | 592 1997 CLINICAL INFECTIOUS DISEASES 24(6):1223-1227 Haslett P; Tramontana J; Burroughs M; Hempstead M; Kaplan G Adverse reactions to thalidomide in patients infected with human immunodeficiency virus | 22 | 30 |
| 685 | 19 | 37 | 708 1998 JOURNAL OF EXPERIMENTAL MEDICINE 187(11):1885-1892 Haslett PAJ; Corral LG; Albert M; Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | 144 | 179 |
| 686 | 19 | 40 | 1750 2003 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
| 687 | 12 | 39 | 746 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
| 688 | 4 | 25 | 64 1983 ARCHIVES OF DERMATOLOGY 119(10):812-815 HASPER MF CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS - THALIDOMIDE TREATMENT OF 11 PATIENTS | 21 | 32 |
| 689 | 0 | 0 | 67 1983 BRITISH JOURNAL OF DERMATOLOGY 108(1):109-109 HASPER MF THE EFFECT OF THALIDOMIDE IN THE TREATMENT OF LUPUS-ERYTHEMATOSUS | 0 | 0 |
| 690 | 0 | 20 | 35 1982 ACTA DERMATO-VENEREOLOGICA 62(4):321-324 HASPER MF; KLOKKE AH THALIDOMIDE IN THE TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 17 | 23 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 691 | 0 | 1 | 111 1984 BRITISH MEDICAL JOURNAL 289(6456):1424-1424 HASSAN EM; GOSSMAN HH THALIDOMIDE AND MULTIPLE CEREBRAL ANEURYSMS - FORTUITOUS OR CAUSAL ASSOCIATION | 0 | 0 |
| 692 | 0 | 0 | 4 1981 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 181(MAR):68-MEDI HASSAN KM; AGRAWAL KC; HASTINGS RC ANTI-INFLAMMATORY - IMMUNOSUPPRESSIVE THALIDOMIDE ANALOGS | 0 | 0 |
| 693 | 1 | 20 | 312 1991 LEUKEMIA RESEARCH 15(2-3):129-136 HATFILL SJ; FESTER ED; DEBEER DP; BOHM L INDUCTION OF MORPHOLOGICAL-DIFFERENTIATION IN THE HUMAN LEUKEMIC-CELL LINE K562 BY EXPOSURE TO THALIDOMIDE METABOLITES | 17 | 20 |
| 694 | 0 | 0 | 1471 2002 INTERNATIONAL JOURNAL OF CANCER :402-402 Hatjiharissi E; Gerotziafas G; Hatjileontis C; Galaktidou G; Bakaloudi V; Papaioannou M; Kaloutsi V; Kortsaris A; Christakis J; Zervas K Study of neoangiogenesis and cytokine serum levels in patients with refractory multiple myeloma treated with thalidomide-dexamethasone | 0 | 0 |
| 695 | 0 | 0 | 1469 2002 INTERNATIONAL JOURNAL OF CANCER :104-104 Hatjiharissi E; Gerotziafas G; Papaioannou M; Bakaloudi V; Tokmaktsis A; Kaloutsi V; Christakis J; Zervas K Efficacy and tolerability of combination thalidomide-dexamethasone in multiple myeloma patients with refractory disease | 0 | 0 |
| 696 | 0 | 0 | 1652 2003 BLOOD 102(11):689A-689A Hattori Y; Kakimoto T; Okamoto S; Iguchi T; Morita K; Tanigawara Y; Ikeda Y Plasma concentration of thalidomide and clinical efficacy in patients with multiple myeloma. | 0 | 0 |
| 697 | 17 | 25 | 1915 2004 INTERNATIONAL JOURNAL OF HEMATOLOGY 79(3):283-288 Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y Thalidomide-induced severe neutropenia during treatment of multiple myeloma | 0 | 0 |
| 698 | 6 | 22 | 588 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 108(3):428-431 Hauschild A; Kroeger H; Mitchison NA; Ugrinovic S; Zwingenberger K Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift | 6 | 12 |
| 699 | 0 | 1 | 330 1992 LANCET 339(8800):1057-1057 HAWKINS DF THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 7 | 8 |
| 700 | 0 | 0 | 1341 2002 BLOOD 100(11):314B-314B Hayashi T; Anderson KC; Steven SP Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 701 | 0 | 0 | 1387 2002 BLOOD 100(11):815A-815A Hayashi T; Hideshima T; Akiyama M; Munshi N; Chauhan D; Anderson KC Mechanisms whereby immunomedulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity. | 0 | 1 |
| 702 | 5 | 10 | 1729 2003 INTERNAL MEDICINE 42(7):605-608 Hayashi T; Yamaguchi I; Saitoh H; Takagi M; Nonaka Y; Nomura T Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis | 1 | 2 |
| 703 | 0 | 0 | 345 1993 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 206:216-MEDI HE WX; ENGSTROM L; WALKER S; VOGELSANG G; LEONG KW SYNTHESIS OF THALIDOMIDE ANALOGS AND THEIR BIOLOGICAL POTENTIAL FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 0 | 0 |
| 704 | 3 | 6 | 254 1989 BONE MARROW TRANSPLANTATION 4(5):598-598 HEATON DC FAILURE OF THALIDOMIDE TO CONTROL BRONCHIOLITIS OBLITERANS POST BONE-MARROW TRANSPLANT | 1 | 3 |
| 705 | 9 | 14 | 717 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 38(3):490-491 Hecker MS; Lebwohl MG Recalcitrant pyoderma gangrenosum: Treatment with thalidomide | 14 | 21 |
| 706 | 0 | 0 | 1497 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(1):212-212 Heere-Ress E; Boehm J; Hoeller C; Thallinger C; Wolff K; Pehamberger H; Jansen B Anti-tumor effect of thalidomide and dacarbazine in melanoma SCID mouse model | 0 | 0 |
| 707 | 0 | 0 | 1928 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 123(2) Heere-Ress E; Boehm J; Hoeller C; Wacheck V; Thallinger C; Wolff K; Jansen B; Pehamberger H Thalidomide combined with dacarbazine enhances the anti-tumor activity in a human melanoma xenotransplantation model | 0 | 0 |
| 708 | 44 | 67 | 1806 2003 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 95(5):576-585 Hegarty A; Hodgson T; Porter S Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis | 1 | 2 |
| 709 | 2 | 15 | 225 1988 ARCHIVES OF TOXICOLOGY 62(2-3):205-208 HEGER W; KLUG S; SCHMAHL HJ; NAU H; MERKER HJ; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES ON THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .3. TERATOGENIC POTENCY OF THE EM-12 ENANTIOMERS | 6 | 13 |
| 710 | 0 | 0 | 197 1986 TERATOLOGY 34(3):415-415 HEGER W; SAMES K; MERKER HJ; FRANKUS E; GRAUDUMS I; NEUBERT D TERATOGENIC EVALUATION OF A METHYLATED THALIDOMIDE DERIVATIVE IN A PRIMATE SPECIES | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 711 | 5 | 20 | 428 1994 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 14(3):115-122 HEGER W; SCHMAHL HJ; KLUG S; FELIES A; NAU H; MERKER HJ; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NONHUMAN PRIMATE CALLITHRIX-JACCHUS .4. TERATOGENICITY OF MU-G/KG DOSES OF THE EM12 ENANTIOMERS | 7 | 15 |
| 712 | 0 | 0 | 1356 2002 BLOOD 100(11):387B-387B Helgason HH; Smit WM; de Groot MR; Schenkeveld CEI; Neef C; Schaafsma MR Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide. | 0 | 0 |
| 713 | 0 | 0 | 54 1982 TERATOLOGY 25(2):A47-A47 HELM FC; FRANKUS E CHEMICAL-STRUCTURE AND TERATOGENIC ACTIVITY OF THALIDOMIDE-RELATED COMPOUNDS | 4 | 4 |
| 714 | 0 | 39 | 9 1981 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 31-1(6):941-949 HELM FC; FRANKUS E; FRIDERICHS E; GRAUDUMS I; FLOHE L COMPARATIVE TERATOLOGICAL INVESTIGATION OF COMPOUNDS STRUCTURALLY AND PHARMACOLOGICALLY RELATED TO THALIDOMIDE | 0 | 54 |
| 715 | 1 | 36 | 90 1983 MEDICAL HYPOTHESES 10(4):437-443 HENDLER SS; MCCARTY MF THALIDOMIDE FOR AUTOIMMUNE-DISEASE | 13 | 14 |
| 716 | 19 | 39 | 270 1990 BIOMEDICINE & PHARMACOTHERAPY 44(4):199-204 HENEY D; BAILEY CC; LEWIS IJ THALIDOMIDE IN THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 12 | 14 |
| 717 | 3 | 3 | 239 1988 LANCET 2(8623):1317-1317 HENEY D; LEWIS IJ; BAILEY CC THALIDOMIDE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 9 | 14 |
| 718 | 11 | 20 | 301 1991 BRITISH JOURNAL OF HAEMATOLOGY 78(1):23-27 HENEY D; NORFOLK DR; WHEELDON J; BAILEY CC; LEWIS IJ; BARNARD DL THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 59 | 72 |
| 719 | 13 | 36 | 1746 2003 JOURNAL OF CLINICAL ONCOLOGY 21(20):3770-3776 Hernberg M; Virkkunen P; Bono P; Atinen H; Maenpaa H; Joensuu H Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma | 2 | 4 |
| 720 | 6 | 10 | 691 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(5):233-235 Herranz P; Pizarro A; de Lucas R; Arribas JR; Garcia-Tobaruela A; Pena JM; Casado M Treatment of AIDS-associated prurigo nodularis with thalidomide | 4 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 721 | 15 | 15 | 1875 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(2):101-104 Hershfield NB Disappearance of Chron's ulcers in the terminal ileum after thalidomide therapy | 0 | 0 |
| 722 | 0 | 0 | 1876 2004 CANADIAN JOURNAL OF GASTROENTEROLOGY 18(6):419-419 Hershfield NB Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. Response | 0 | 0 |
| 723 | 6 | 28 | 187 1986 JOURNAL OF NEUROLOGY 233(2):83-89 HESS CW; HUNZIKER T; KUPFER A; LUDIN HP THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - A PROSPECTIVE CLINICAL, NEUROPHYSIOLOGICAL AND PHARMACOGENETIC EVALUATION | 26 | 30 |
| 724 | 0 | 0 | 221 1988 ARCHIV DER PHARMAZIE 321(9):602-602 HESS HR; BLASCHKE G HYDROXYLATION, A STEP IN THALIDOMIDE METABOLIZATION | 0 | 0 |
| 725 | 13 | 41 | 1091 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(5):1279-1291 Hess S; Akermann MA; Wnendt S; Zwingerberger K; Eger K Synthesis and immunological activity of water-soluble thalidomide prodrugs | 2 | 4 |
| 726 | 0 | 0 | 925 2000 BLOOD 96(11):304A-304A Hideshima T; Chauhan D; Shima Y; Noopur R; Davies FE; Tai YT; Treon SP; Lin BK; Schlossman RL; Richardson PG; Gupta D; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy. | 0 | 0 |
| 727 | 10 | 31 | 896 2000 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 90 | 173 |
| 728 | 2 | 2 | 331 1992 LANCET 339(8805):1362-1362 HIGGINS SP; BRADBEER CS THALIDOMIDE - A RESTRICTED ROLE | 0 | 0 |
| 729 | 5 | 20 | 1206 2001 HAUTARZT 52:962-965 Hoch O; Muller S; Buttner G; Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 3 | 5 |
| 730 | 0 | 9 | 373 1993 PHARMAZIE 48(2):147-148 HOFENEDER M; KREBS G; SUTTER B; KOCH HP ACUTE TOXICITY OF THALIDOMIDE, TAGLUTIMIDE AND SUPIDIMIDE IN THE YEAST-TEST | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 731 | 0 | 1 | 347 1993 AMERICAN SCIENTIST 81(5):425-426 HOFFMAN M A 2ND CHANCE FOR THALIDOMIDE | 0 | 0 |
| 732 | 12 | 33 | 714 1998 JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 26(4):363-383 Hoglund P; Eriksson T; Bjorkman S A double-blind study of the sedative effects of the thalidomide enantiomers in humans | 11 | 15 |
| 733 | 8 | 13 | 349 1993 ARCHIVES OF DERMATOLOGY 129(12):1548-1550 HOLM AL; BOWERS KE; MCMEEKIN TO; GASPARI AA CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS TREATED WITH THALIDOMIDE | 17 | 20 |
| 734 | 2 | 11 | 305 1991 BRITISH MEDICAL JOURNAL 303(6814):1404-1405 HOOPER M USE OF THALIDOMIDE IN LEPROSY | 2 | 2 |
| 735 | 15 | 21 | 1811 2003 PHARMACOTHERAPY 23(3):315-318 Horne MK; Figg WD; Arlen P; Gulley J; Parker C; Lakhani N; Parnes H; Dahut WL Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer | 3 | 4 |
| 736 | 11 | 22 | 861 1999 PHARMACOTHERAPY 19(10):1177-1180 Horowitz SB; Stirling AL Thalidomide-induced toxic epidermal necrolysis | 10 | 10 |
| 737 | 0 | 1 | 1251 2001 NEW YORK REVIEW OF BOOKS 48(8):12-15 Horton R Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 738 | 11 | 30 | 1588 2003 ARCHIVES OF DERMATOLOGY 139(1):50-54 Housman TS; Jorizzo JL; McCarty MA; Grummer SE; Fleischer AB; Sutej PG Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | 2 | 4 |
| 739 | 0 | 0 | 1649 2003 BLOOD 102(11):686A-686A Hovenga S; Daenen SMGJ; de Wolf JTM; van Imhoff GW; Kluin-Nelemans HC; Vellenga E Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study. | 0 | 0 |
| 740 | 0 | 0 | 1863 2004 BONE MARROW TRANSPLANTATION 33:S162-S162 Hoyer B; Fenk R; Steidl U; Germing U; Haas R; Kobbe G Treatment of patients with multiple myeloma in first relapse after high-dose chemotherapy with single agent thalidomide - duration of first remission is the major prognostic factor for EFS and OS | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 741 | 0 | 0 | 1654 2003 BLOOD 102(11):691A-692A Hoyer B; Fenk R; Steidl U; Kondakci M; Germing U; Haas R; Kobbe G Single agent thalidomide for treatment of first relapse following high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. | 0 | 0 |
| 742 | 0 | 0 | 1174 2001 CLINICAL CANCER RESEARCH 7(11):3666S-3667S Hsu C; Chen C; Chen L; Wu C; Hsieh F; Cheng A Use of thalidomide in the treatment of advanced hepatocellular carcinoma (HCC): With emphasis on using power Doppler sonography to evaluate the vascularity of the tumor and its correlation with tumor response. | 0 | 0 |
| 743 | 13 | 44 | 1805 2003 ONCOLOGY 65(3):242-249 Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL Low-dose thalidomide treatment for advanced hepatocellular carcinoma | 2 | 5 |
| 744 | 0 | 0 | 1691 2003 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 12(11):1288S-1288S Hsu C; Chen HN; Chen LT; Wu CY; Hsieh FJ; Cheng AL Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma. | 0 | 0 |
| 745 | 0 | 0 | 1556 2003 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U196-U197 Hu ZG; Pandit B; Shi JD; Zink J; Sackett DL; Li PK Thalidomide analogs with antiproliferative and antimicrotubule activities. | 0 | 0 |
| 746 | 0 | 0 | 1279 2002 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 224:U21-U21 Hu ZG; Zink J; Zili X; Shi JD; Li PK Anti-angiogenic and anti-proliferative thalidomide analogs. | 0 | 0 |
| 747 | 0 | 0 | 892 2000 ARTHRITIS AND RHEUMATISM 43(9):S396-S396 Huang F; Gu J; Braun J; Sieper J; Yu DT Identifying the targets of thalidomide and anti-TNF alpha antibody treatments in ankylosing spondylitis (AS). | 2 | 5 |
| 748 | 0 | 0 | 1081 2001 ARTHRITIS AND RHEUMATISM 44(9):S275-S275 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis (AS). | 0 | 2 |
| 749 | 8 | 14 | 1302 2002 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 47(3):249-254 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY One-year open-label trial of thalidomide in ankylosing spondylitis | 3 | 11 |
| 750 | 14 | 18 | 1424 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161 Huang F; Wei JCC; Breban M Thalidomide in ankylosing spondylitis | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 751 | 0 | 0 | 1361 2002 BLOOD 100(11):389B-389B Huang JW; Wang YH; Du HP; Zhang J Thalidomide combined with conventional melphalan and predisone regimen for treatment of mulitiple myeloma | 0 | 0 |
| 752 | 6 | 38 | 293 1990 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 10(4):281-294 HUANG PHT; MCBRIDE WG THALIDOMIDE INDUCED ALTERATION IN SECONDARY STRUCTURE OF RAT EMBRYONIC DNA INVIVO | 6 | 12 |
| 753 | 3 | 13 | 652 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):1-5 Huang PHT; McBride WG Interaction of [glutarimide-2-C-14]-thalidomide with rat embryonic DNA in vivo | 7 | 12 |
| 754 | 3 | 8 | 860 1999 PHARMACOLOGY & TOXICOLOGY 85(2):103-104 Huang PHT; McBride WG; Tuman WG Interaction of thalidomide with DNA of rabbit embryos: A possible explanation for its immunosuppressant and teratogenic effects | 3 | 3 |
| 755 | 27 | 37 | 1576 2003 ANNALS OF HEMATOLOGY 82(9):558-564 Huang SY; Tang JL; Yao M; Ko BS; Hong RL; Tsai W; Wang CH; Tien HF; Shen MC; Chen YC Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma | 0 | 0 |
| 756 | 0 | 0 | 623 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):721-721 Hughes MH; Brander TR; Aronson IK; Eilers D; Fiedler BC Thalidomide therapy for discoid and systemic lupus erythematosus. | 0 | 0 |
| 757 | 5 | 14 | 498 1996 ANNALS OF THE RHEUMATIC DISEASES 55(11):833-836 Huizinga TWJ; Dijkmans BAC; vanderVelde EA; Kraan TCTMV; Verweij CL; Breedveld FC An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis | 20 | 37 |
| 758 | 0 | 0 | 209 1987 EXPERIMENTAL HEMATOLOGY 15(5):476-476 HULLIN R; VOGELSANG GB; BRUNDRETTE R; COLVIN OM; SANTOS GW; HESS AD INTRACELLULAR BINDING-PROTEINS FOR THALIDOMIDE | 0 | 0 |
| 759 | 0 | 0 | 399 1994 CHEMISTRY IN BRITAIN 30(4):280-280 HUNT JR THALIDOMIDE DEBATE | 0 | 0 |
| 760 | 2 | 66 | 85 1983 HAUTARZT 34(2):66-72 HUNZIKER T; KREBS A THALIDOMIDE IN DERMATOLOGY | 7 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 761 | 0 | 0 | 1143 2001 BONE MARROW TRANSPLANTATION 27:S251-S252 Hus M; Dmoszynska A; Legiec W; Jawniak D; Soroka-Wojtaszko M; Manko J Thalidomide as a preparative regimen and late stem cell transplantation in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| 762 | 5 | 21 | 1201 2001 HAEMATOLOGICA 86(4):404-408 Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J; Polish Multiple Myeloma Study Grp Thalidomide treatment of resistant or relapsed multiple myeloma patients | 23 | 35 |
| 763 | 0 | 4 | 1603 2003 BLOOD 102(1):2-3 Hussein MA Thalidomide, age, and future use in multiple myeloma | 0 | 0 |
| 764 | 3 | 31 | 1804 2003 ONCOLOGIST 8:39-45 Hussein MA Modifications to therapy for multiple myeloma: Pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide | 0 | 1 |
| 765 | 0 | 0 | 1376 2002 BLOOD 100(11):403A-403A Hussein MA; Elson P; Tsoe EA; Karam M; Srkaloci G Doxil (D), vincristine (V), decadron (D) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM). | 0 | 5 |
| 766 | 4 | 6 | 449 1995 CLINICAL CHEMISTRY 41(8):1199-1199 HUUPPONEN R; PYYKKO K STABILITY OF THALIDOMIDE IN HUMAN PLASMA | 6 | 8 |
| 767 | 0 | 7 | 314 1991 NEURO-OPHTHALMOLOGY 11(1):29-32 HUYGEN PLM; VANRIJN PM; VERHAGEN WIM; CREMERS CWRJ; THEUNISSEN EJJM SUBCORTICAL OPTOKINETIC RESPONSE IN A CASE OF THALIDOMIDE FETOPATHY | 0 | 1 |
| 768 | 7 | 16 | 1040 2000 ONCOLOGY-NEW YORK 14(12):25-28 Hwu WJ New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide | 6 | 14 |
| 769 | 2 | 8 | 1256 2001 ONCOLOGY-NEW YORK 15(7):878-879 Hwu WJ Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
| 770 | 7 | 26 | 1745 2003 JOURNAL OF CLINICAL ONCOLOGY 21(17):3351-3356 Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma | 4 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 771 | 6 | 26 | 1488 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial | 12 | 22 |
| 772 | 1 | 1 | 1489 2002 JOURNAL OF CLINICAL ONCOLOGY 20(15):3361-3361 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial (vol 20, pg 2610, 2002) | 0 | 0 |
| 773 | 0 | 5 | 1237 2001 LANCET ONCOLOGY 2(10):634-635 Hwu WJ; Raizer J; Panageas KS; Lis E Treatment of metastatic melanoma in the brain with temozolomide and thalidomide | 3 | 7 |
| 774 | 2 | 4 | 496 1996 AMERICAN JOURNAL OF OPHTHALMOLOGY 122(4):594-595 Ip M; Gorin MB Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide | 4 | 13 |
| 775 | 0 | 0 | 968 2000 DIABETES 49:A434-A434 Iqbal N; Boden G Thalidomide impairs insulin stimulated glucose uptake in patients with type 2 diabetes (T2DM) by inhibiting glycogen synthesis | 0 | 0 |
| 776 | 7 | 23 | 969 2000 DIABETES CARE 23(8):1172-1176 Iqbal N; Zayed M; Boden G Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes | 3 | 3 |
| 777 | 5 | 15 | 671 1998 BIOLOGICAL & PHARMACEUTICAL BULLETIN 21(6):638-640 Ishikawa M; Kanno S; Takayanagi M; Takayanagi Y; Sasaki K Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice | 5 | 6 |
| 778 | 0 | 0 | 1345 2002 BLOOD 100(11):341B-341B Islam A; Bielat K; Smith G Does thalidomide have an effect other than anti-angiogenesis. | 0 | 0 |
| 779 | 5 | 22 | 1831 2004 ACTA NEUROLOGICA SCANDINAVICA 109(3):188-193 Isoardo G; Bergui M; Durelli L; Barbero P; Boccadoro M; Bertola A; Ciaramitaro P; Palumbo A; Bergamasco B; Cocito D Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features | 0 | 0 |
| 780 | 0 | 0 | 128 1984 TERATOLOGY 30(1):A26-A26 IWAKURA H; YOSHIDA K; OGAWA T PHYSICAL-EXAMINATION OF THALIDOMIDE EMBRYOPATHY PATIENTS - PROBLEMS OF MOTOR DYSFUNCTION | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 781 | 0 | 1 | 646 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1087-1087 Jacobson JM; Greenspan JS; Spritzler J Thalidomide for aphthous ulcers in HIV infection - Reply | 0 | 0 |
| 782 | 4 | 10 | 1228 2001 JOURNAL OF INFECTIOUS DISEASES 183(2):343-346 Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C; Natl Inst Allergy Infect Dis AIDS Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers | 1 | 3 |
| 783 | 21 | 44 | 644 1997 NEW ENGLAND JOURNAL OF MEDICINE 336(21):1487-1493 Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection | 119 | 192 |
| 784 | 6 | 17 | 828 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):61-67 Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N; Natl Inst Allergy Infect Dis AIDS Clin Trials G Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection | 27 | 38 |
| 785 | 0 | 0 | 1190 2001 FASEB JOURNAL 15(4):A556-A556 Jajeh A; Boulos B; Youakim J; Ali M; Woynarowsky A In vitro reduction of accelerated apoptosis of neutrophils in blood drawn from an HIV positive subject with Thalidomide. | 0 | 0 |
| 786 | 4 | 12 | 412 1994 LANCET 343(8895):432-433 JAKEMAN P; SMITH WCS THALIDOMIDE IN LEPROSY REACTION | 8 | 14 |
| 787 | 0 | 0 | 857 1999 PEDIATRIC RESEARCH 45(4):67A-67A Jakkula M; Le Cras TD; Abman SH Effects of fumagillin and thalidomide treatment on alveolarization in the developing rat lung | 0 | 4 |
| 788 | 0 | 0 | 995 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Jakobezyk-Zmija M; Kaven C; Spraul CW; Lang GK; Lang GE Effect of thalidomide and prednisolone on the secretion of growth factors by human RPE cells in vitro | 0 | 0 |
| 789 | 0 | 0 | 619 1997 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 99(1):679-679 James DE; Jaffarian A; Biggs DF The effects of thalidomide on TNF alpha production from guinea pig alveolar macrophages in vitro and on airways' hyperresponsiveness in vivo. | 0 | 0 |
| 790 | 0 | 0 | 977 2000 EXPERIMENTAL HEMATOLOGY 28(7):110-110 Janssen WE; Dalton WS Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 791 | 19 | 51 | 1416 2002 CANCER INVESTIGATION 20(7-8):1051-1058 Jaslow R; Kaplan G; Lyons L; Michaeli J; Coleman M Thalidomide in multiple myeloma-from the clinic to the laboratory | 0 | 0 |
| 792 | 10 | 16 | 1587 2003 ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX 96(10):1006-1010 Jego C; Barbou F; Laurent P; Gisserot O; Cellarier G; Bonal J; Bouchiat C; Landais C; de Jaureguiberry JP; Dussarat GV Left atrial thrombus in the course of multiple myeloma treated with thalidomide | 0 | 0 |
| 793 | 2 | 11 | 123 1984 LANCET 2(8417):1424-1426 JENKINS JS; POWELL RJ; ALLEN BR; LITTLEWOOD SM; MAURICE PDL; SMITH NJ THALIDOMIDE IN SEVERE OROGENITAL ULCERATION | 25 | 35 |
| 794 | 1 | 1 | 145 1985 BRITISH JOURNAL OF RHEUMATOLOGY 24(1):95-96 JENKINS JS; POWELL RJ; MAURICE P; LITTLEWOOD S; ALLEN BR THALIDOMIDE IN THE TREATMENT OF OROGENITAL ULCERATION | 0 | 0 |
| 795 | 1 | 2 | 162 1985 LANCET 1(8427):511-511 JENKINS S; POWELL RJ; ALLEN BR; LITTLEWOOD S; MAURICE PD; SMITH NJ THALIDOMIDE, OROGENITAL ULCERS, AND RISK OF TERATOGENICITY | 2 | 3 |
| 796 | 0 | 7 | 273 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(5):482-483 JEW LJ; MIDDLETON RK THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM | 0 | 0 |
| 797 | 0 | 0 | 1927 2004 JOURNAL OF INVESTIGATIVE DERMATOLOGY 122(3):A7-A7 Jin JH; Zhang W; Werth VP Thalidomide inhibits the induction of tumor necrosis factor-alpha by ultraviolet B irradiation of human keratinocytes | 0 | 0 |
| 798 | 4 | 5 | 1417 2002 CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS 973:414-418 Jin SH; Il Kim T; Han DS; Shin SK; Kim WH Thalidomide suppresses the interleukin 1 beta-induced NF kappa B signaling pathway in colon cancer cells | 1 | 3 |
| 799 | 0 | 0 | 1722 2003 GASTROENTEROLOGY 124(4):A10-A10 Jin SH; Kim WH; Kim TI; Yang KM; Shin SK; Lee SK; Park SJ; Choi CH; Lee WJ Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR | 0 | 0 |
| 800 | 24 | 52 | 1895 2004 DRUGS OF TODAY 40(3):197-204 Joglekar S; Levin M The promise of thalidomide: Evolving indications | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 801 | 0 | 0 | 355 1993 BRITISH MEDICAL JOURNAL 307(6901):404-404 JOHN D DOCTOR WHO FOUND THALIDOMIDE DANGERS IS STRUCK OFF | 0 | 0 |
| 802 | 7 | 8 | 1520 2002 LEUKEMIA & LYMPHOMA 43(2):351-354 Johnston RE; Abdalla SH Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia | 7 | 9 |
| 803 | 2 | 5 | 414 1994 LANCET 343(8904):1041-1041 JONES GRN THALIDOMIDE - 35 YEARS ON AND STILL DEFORMING | 4 | 5 |
| 804 | 0 | 4 | 1405 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(2):576-577 Jones SG; Dolan G; Lengyel K; Myers B Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions | 0 | 3 |
| 805 | 0 | 2 | 16 1981 INTERNATIONAL JOURNAL OF DERMATOLOGY 20(3):220-220 JOPLING WH THALIDOMIDE | 0 | 0 |
| 806 | 5 | 19 | 176 1986 ARCHIVES OF INTERNAL MEDICINE 146(5):878-881 JORIZZO JL; SCHMALSTIEG FC; SOLOMON AR; CAVALLO T; TAYLOR RS; RUDLOFF HB; SCHMALSTIEG EJ; DANIELS JC THALIDOMIDE EFFECTS IN BEHCETS-SYNDROME AND PUSTULAR VASCULITIS | 25 | 59 |
| 807 | 3 | 3 | 1938 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(3):480-481 Jouanique C; Reygagne P; Bachelez H; Dubertret L Thalidomide is ineffective in the treatment of lichen planopilaris | 0 | 0 |
| 808 | 7 | 33 | 810 1999 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 237(12):952-961 Joussen AM; Germann T; Kirchhof B Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency | 4 | 8 |
| 809 | 0 | 2 | 611 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1680-1680 Joussen AM; Kruse FE; Becker M; Rohrschneider K; Volcker HE Thalidomide inhibits angiogenesis induced by vascular endothelial growth factor | 0 | 0 |
| 810 | 0 | 0 | 962 2000 CLINICAL INFECTIOUS DISEASES 31(1):312-312 Joyce MP; Sandoval FG; Shannon EJ Thalidomide's effect on immune parameters in untreated lepromatous leprosy and erythema nodosum leprosum | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 811 | 1 | 1 | 483 1995 POSTGRADUATE MEDICAL JOURNAL 71(832):123-123 JUDGE MR; KOBZABLACK A; HAWK JLM GUIDELINES FOR THE CLINICAL USE AND DISPENSING OF THALIDOMIDE | 0 | 0 |
| 812 | 9 | 15 | 1009 2000 JOURNAL OF INFECTIOUS DISEASES 181(5):1813-1816 Juffermans NP; Verbon A; Olszyna DP; van Deventer SJH; Speelman P; van der Poll T Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4(+) T cells in humans | 3 | 5 |
| 813 | 5 | 14 | 1077 2001 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 45(5):1547-1549 Juffermans NP; Verbon A; Schultz MJ; Hack CE; van Deventer SJH; Speelman P; van der Poll T Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens | 2 | 2 |
| 814 | 0 | 0 | 764 1999 BLOOD 94(10):124A-124A Juliusson G; Celsing F; Turesson I; Adriansson M; Malm C Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 0 | 2 |
| 815 | 8 | 19 | 948 2000 BRITISH JOURNAL OF HAEMATOLOGY 109(1):89-96 Juliusson G; Celsing F; Turesson I; Lenhoff S; Adriansson M; Malm C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma | 88 | 117 |
| 816 | 2 | 5 | 1835 2004 AMERICAN JOURNAL OF HEMATOLOGY 75(3):176-177 Jung CP; Emmerich B; Goebel FD; Bogner JR Successful treatment of a patient with HIV-associated multicentric castleman disease (MCD) with thalidomide | 0 | 0 |
| 817 | 13 | 23 | 1735 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 23(6):1651-1655 Kaicker S; McCrudden KW; Beck L; New T; Huang JZ; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma | 0 | 0 |
| 818 | 0 | 17 | 169 1985 PSYCHOPHARMACOLOGY 85(1):47-50 KAITIN KI EFFECTS OF THALIDOMIDE AND PENTOBARBITAL ON NEURONAL-ACTIVITY IN THE PREOPTIC AREA DURING SLEEP AND WAKEFULNESS IN THE CAT | 3 | 6 |
| 819 | 0 | 0 | 914 2000 BLOOD 96(11):289B-289B Kakimoto T; Hattori Y; Okamoto S; Kamata T; Satoh N; Takayama N; Matsushita H; Yamada T; Du WL; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma. Decreased plasma concentration of angiogenic growth factors and clinical response. | 0 | 0 |
| 820 | 14 | 28 | 1476 2002 JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036 Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | 3 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 821 | 0 | 0 | 1101 2001 BLOOD 98(11):162A-162A Kakimoto T; Hattori Y; Okamoto S; Sato N; Yamaguchi M; Morita K; Yamada T; Takayama N; Shimada N; Tanigawara Y; Ikeda Y Clinical significance of serial monitoring of plasma concentration of thalidomide and angiogenic growth factors in patients with refractory myeloma. | 0 | 1 |
| 822 | 8 | 30 | 865 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):312-316 Kalofoutis A; Monastirli A; Papapanagiotou A; Georgiou S; Pasmatzi E; Sakkis T; Bolsen K; Goerz G; Merk HF; Tsambaos D Alterations of rat liver phospholipid composition induced by oral thalidomide | 0 | 0 |
| 823 | 0 | 0 | 980 2000 GASTROENTEROLOGY 118(4):A582-A582 Kam LY; Vasiliauskas EA; Abreu MT; Hassard PV; Zeldis J; Targan SR Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC). | 1 | 6 |
| 824 | 1 | 1 | 683 1998 BONE MARROW TRANSPLANTATION 22(9):934-934 Kami M; Ogawa S; Mitani K; Hirai H Thalidomide for chronic GVHD - Reply | 0 | 0 |
| 825 | 0 | 0 | 771 1999 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
| 826 | 5 | 25 | 555 1996 NEUROREPORT 7(12):1881-1886 Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy | 1 | 6 |
| 827 | 0 | 6 | 560 1996 SLEEP 19(2):116-116 Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E Thalidomide, immune modulation and narcolepsy | 0 | 2 |
| 828 | 5 | 11 | 866 1999 SLEEP 22(1):113-115 Kanbayashi T; Shimizu T; Takahashi Y; Kitajima T; Takahashi K; Saito Y; Hishikawa Y Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study | 9 | 11 |
| 829 | 10 | 15 | 1481 2002 JOURNAL OF CLINICAL GASTROENTEROLOGY 35(2):149-150 Kane S; Stone LJ; Ehrenpreis E Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab - A case series | 3 | 5 |
| 830 | 0 | 0 | 803 1999 GASTROENTEROLOGY 116(4):A745-A745 Kane SV; Ehrenpreis ED; Cohen LB; Hanauer SB; Cohen RD Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) | 2 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 831 | 0 | 0 | 210 1987 JAPANESE JOURNAL OF PSYCHIATRY AND NEUROLOGY 41(2):197-206 KANNO O ELECTROENCEPHALOGRAPHIC STUDY OF 137 PATIENTS WITH THALIDOMIDE EMBRYOPATHY | 0 | 1 |
| 832 | 0 | 0 | 146 1985 ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY 61(3):S174-S174 KANNO O; KAZAMATSURI H ELECTROENCEPHALOGRAPHIC STUDY ON THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 833 | 0 | 0 | 127 1984 TERATOLOGY 30(1):A26-A26 KANNO O; SAITO T; ASAKA A ELECTROENCEPHALOGRAPHIC STUDY ON THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 834 | 4 | 5 | 1011 2000 JOURNAL OF INFECTIOUS DISEASES 182(2):640-640 Kaplan G Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection - Reply | 0 | 0 |
| 835 | 15 | 19 | 1018 2000 LEPROSY REVIEW 71:S117-S120 Kaplan G Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions | 1 | 2 |
| 836 | 13 | 32 | 873 2000 AIDS RESEARCH AND HUMAN RETROVIRUSES 16(14):1345-1355 Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PAJ; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M Thalidomide for the treatment of AIDS-associated wasting | 13 | 28 |
| 837 | 11 | 41 | 1266 2001 RHEUMATOLOGY 40(8):933-938 Kari JA; Shah V; Dillon MJ Behcet's disease in UK children: clinical features and treatment including thalidomide | 5 | 16 |
| 838 | 29 | 42 | 1242 2001 LUPUS 10(3):188-192 Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV Update on therapy - thalidomide in the treatment of lupus | 6 | 13 |
| 839 | 16 | 42 | 1730 2003 INTERNATIONAL IMMUNOPHARMACOLOGY 3(10-11):1447-1456 Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study | 0 | 1 |
| 840 | 18 | 37 | 1061 2000 TOXICOLOGY AND APPLIED PHARMACOLOGY 165(3):237-244 Karrow NA; McCay JA; Brown RD; Musgrove DL; Pettit DA; Munson AE; Germolec DR; White KL Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice | 5 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 841 | 3 | 3 | 1841 2004 ANNALS OF ONCOLOGY 15(1):176-177 Kasper B; Moehler T; Neben K; Ho AD; Goldschmidt H Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma | 0 | 0 |
| 842 | 0 | 0 | 1123 2001 BLOOD 98(11):309B-309B Kasper B; Moehler TM; Neben K; Ho AD; Goldschmidt H Response to a combination therapy of thalidomide and Pegintron (R) in patients with progressive multiple myeloma (MM). | 0 | 1 |
| 843 | 2 | 2 | 990 2000 INFLAMMATORY BOWEL DISEASES 6(2):152-153 Katz JA Thalidomide for Crohn's disease: High dose, low dose, or "no doze" at all? Comment | 1 | 1 |
| 844 | 8 | 19 | 1580 2003 ANNALS OF PHARMACOTHERAPY 37(7-8):1040-1043 Kaur A; Yu SS; Lee AJ; Chiao TB Thalidomide-induced sinus bradycardia | 1 | 1 |
| 845 | 0 | 0 | 1328 2002 BLOOD 100(11):75B-75B Kaushal V; Kaushal GP; Anaissie EJ; Kurylo P; Kohli M; Fink LM; Mehta P Thalidomide-induced coagulopathy: Evidence for an indirect effect on endothelium. | 0 | 0 |
| 846 | 6 | 33 | 1941 2004 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2(2):327-334 Kaushal V; Kaushal GP; Melkaveri SN; Mehta P Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology | 0 | 0 |
| 847 | 7 | 40 | 1259 2001 OPHTHALMOLOGICA 215(4):284-289 Kaven C; Spraul CW; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro | 2 | 7 |
| 848 | 0 | 0 | 1617 2003 BLOOD 102(11):359B-359B Kay N; Geyer S; Yaqoob I; Phyliky R; Kutteh L; Li CY Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) study. | 0 | 0 |
| 849 | 0 | 0 | 1366 2002 BLOOD 100(11):392B-392B Kazmi MA; Cuadrado MJ; Karim MY; Jones RJ; Khamashta MA; Schey SA Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent. | 0 | 0 |
| 850 | 5 | 30 | 1913 2004 INTERNATIONAL JOURNAL OF CANCER 110(2):260-265 Kedar I; Mermershtain W; Ivgi H Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 851 | 11 | 17 | 315 1991 TRANSPLANTATION 52(5):908-910 KEENAN RJ; EIRAS G; BURCKART GJ; STUART RS; HARDESTY RL; VOGELSANG G; GRIFFITH BP; ZEEVI A IMMUNOSUPPRESSIVE PROPERTIES OF THALIDOMIDE - INHIBITION OF INVITRO LYMPHOCYTE-PROLIFERATION ALONE AND IN COMBINATION WITH CYCLOSPORINE OR FK506 | 39 | 44 |
| 852 | 12 | 18 | 1793 2003 LEUKEMIA & LYMPHOMA 44(11):1943-1946 Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Low dose thalidomide in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| 853 | 10 | 15 | 835 1999 JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 18 |
| 854 | 27 | 53 | 1219 2001 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387 Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity | 33 | 57 |
| 855 | 0 | 1 | 1514 2002 JOURNAL OF THE HISTORY OF BIOLOGY 35(2):387-389 Keiner C Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 856 | 0 | 7 | 246 1988 TERATOLOGY 38(3):221-226 KELSEY FO THALIDOMIDE UPDATE - REGULATORY ASPECTS | 17 | 29 |
| 857 | 0 | 0 | 699 1998 GASTROENTEROLOGY 114(4):A1008-A1008 Kenet G; Avni Y; Aeed H; Shirin H; Matas Z; Zaidel L; Galor S; Hershkovitz R; Bruck R Iodoacetamide-induced colitis in rats is inhibited by thalidomide. | 0 | 0 |
| 858 | 12 | 25 | 1216 2001 ISRAEL MEDICAL ASSOCIATION JOURNAL 3(9):644-648 Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R Amelioration of experimental colitis by thalidomide | 1 | 1 |
| 859 | 11 | 41 | 600 1997 EXPERIMENTAL EYE RESEARCH 64(6):971-978 Kenyon BM; Browne F; DAmato RJ Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | 97 | 150 |
| 860 | 0 | 0 | 659 1998 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 55(17):1746-+ Kepple SR Thalidomide approval brings tight restrictions on access | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 861 | 1 | 1 | 747 1999 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 56(17):1721-1725 Keravich DP; Daniels CE Challenges of thalidomide distribution in a hospital setting | 0 | 0 |
| 862 | 23 | 45 | 952 2000 CANCER CHEMOTHERAPY AND PHARMACOLOGY 46(2):135-141 Kestell P; Zhao LL; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide | 6 | 21 |
| 863 | 0 | 0 | 1360 2002 BLOOD 100(11):389B-389B Keyzner A; Kumar A; Besa EC The role of thalidomide and pamidronate in maintenance of plateau phase after second and third induction therapy in relapsed multiple myeloma patients. | 0 | 0 |
| 864 | 0 | 0 | 1193 2001 GASTROENTEROLOGY 120(5):A611-A612 Khan ZH; Cole AT; MacDonald I; Pye D; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancers | 0 | 0 |
| 865 | 0 | 0 | 1196 2001 GUT 48:A48-A48 Khan ZH; Cole AT; Macdonald I; Pye D; Simpson L; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancer | 0 | 0 |
| 866 | 0 | 0 | 1457 2002 GUT 50:A4-A4 Khan ZH; Simpson E; Cole AT; Macdonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: The effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study | 1 | 1 |
| 867 | 11 | 28 | 1562 2003 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 17(5):677-682 Khan ZH; Simpson EJ; Cole AT; Holt M; MacDonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass | 0 | 1 |
| 868 | 0 | 0 | 1247 2001 NEUROLOGY 56(8):A208-A209 Khella SL; Souayah N; AMDATS Study Grp Thalidomide polyneuropathy: A prospective double-masked placebo-controlled study in an elderly population with age-related macular degeneration | 0 | 0 |
| 869 | 0 | 0 | 130 1984 TERATOLOGY 30(1):A27-A27 KIDA M MEDICAL-EXAMINATION OF THALIDOMIDE-EMBRYOPATHY - METHODOLOGY AND SUMMARY | 0 | 0 |
| 870 | 0 | 0 | 216 1987 TERATOLOGY 36(3):435-435 KIDA M A QUARTER CENTURY IN THE THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 871 | 1 | 1 | 396 1994 BRITISH MEDICAL JOURNAL 309(6956):741-741 KIDA M THALIDOMIDE MAY NOT BE A MUTAGEN | 5 | 7 |
| 872 | 0 | 0 | 134 1984 TERATOLOGY 30(1):A37-A37 KIKUCHI S ANOMALIES OF THE ORAL AND MAXILLO-FACIAL REGIONS IN THALIDOMIDE EMBRYOPATHY (JAPAN) | 0 | 0 |
| 873 | 0 | 0 | 1454 2002 GASTROENTEROLOGY 122(4):A395-A395 Kim JW; Kim SG; Kim HD; Kim CG; Kim BG; Kim JS; Jung HC; Song IS Effect of DA-6034 and thalidomide on trinitrobenzene sulfonic acid-induced murine ileitis | 0 | 0 |
| 874 | 0 | 0 | 1723 2003 GASTROENTEROLOGY 124(4):A336-A336 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on NF-R activity and TNF-production stimulated with lipopolysaccharide in a human colonic epithelial cell line ka | 0 | 0 |
| 875 | 21 | 45 | 1964 2004 MOLECULES AND CELLS 17(2):210-216 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on the stimulation of NF-kappa B activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line | 0 | 0 |
| 876 | 0 | 0 | 135 1985 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 189(APR-):21-MEDI KING BT; AGRAWAL KC; MORALES MJ; HASTINGS RC ANTIINFLAMMATORY IMMUNOSUPPRESSIVE THALIDOMIDE ANALOGS | 0 | 0 |
| 877 | 6 | 28 | 1502 2002 JOURNAL OF NUCLEAR MEDICINE 43(8):1084-1089 Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts | 1 | 7 |
| 878 | 0 | 0 | 1501 2002 JOURNAL OF NUCLEAR MEDICINE 43(5):267P-267P Kinuya S; Yokoyama K; Li XF; Bai J; Michigishi T; Tonami N Radioimmunotherapy with I-131-monoclonal antibody and antiangiogenic therapy with thalidomide in colon cancer xenografts. | 0 | 0 |
| 879 | 0 | 0 | 1696 2003 CIRCULATION 108(17):170-170 Kirchmair R; Murayama T; Rittig K; Tietz A; Walter D; Schratzberger P; Weinberg DH; Ropper AH; Isner JM Therapeutic angiogenesis inhibits and rescues chemotherapy induced peripheral neuropathy: Taxol, cisplatin and thalidomide induced injury vasa nervorum is ameliorated by VEGF gene therapy | 0 | 0 |
| 880 | 0 | 0 | 1168 2001 CIRCULATION 104(17):566-566 Kishan CV; Saucedo JF; Fahdi I; Gaddam V; Razek H; Bissett JK; Anaissie E; Barlogie B; Mehta JL High dose thalidomide is associated with symptomatic bradycardia | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 881 | 1 | 1 | 1031 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(13):975-975 Kishi Y; Oki Y; Machida U Thalidomide in multiple myeloma | 3 | 5 |
| 882 | 0 | 28 | 3 1980 INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY 18:403-409 KLASINC L; TRINAJSTIC N; KNOP JV APPLICATION OF PHOTOELECTRON-SPECTROSCOPY TO BIOLOGICALLY-ACTIVE MOLECULES AND THEIR CONSTITUENT PARTS .8. THALIDOMIDE | 0 | 0 |
| 883 | 6 | 36 | 518 1996 CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 81(3):219-223 Klausner JD; Freedman VH; Kaplan G Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use | 40 | 57 |
| 884 | 4 | 5 | 837 1999 LANCET 353(9149):324-324 Klausner JD; Kaplan G; Haslett PAJ Thalidomide in toxic epidermal necrolysis | 7 | 8 |
| 885 | 6 | 33 | 540 1996 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 11(3):247-257 Klausner JD; Makonkawkeyoon S; Akarasewi P; Nakata K; Kasinrerk W; Corral L; Dewar RL; Lane HC; Freedman VH; Kaplan G The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M-tuberculosis infection | 51 | 126 |
| 886 | 4 | 10 | 383 1994 ARCHIVES OF TOXICOLOGY 68(3):203-205 KLUG S; FELIES A; STURJE H; NOGUEIRA AC; NEUBERT R; FRANKUS E EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NONHUMAN PRIMATE CALLITHRIX-JACCHUS .5. LACK OF TERATOGENIC EFFECTS OF PHTHALIMIDOPHTHALIMIDE | 4 | 7 |
| 887 | 0 | 17 | 251 1989 ARCHIV DER PHARMAZIE 322(8):499-505 KNABE J; OMLOR G SYNTHESES OF THE RACEMATES AND THE ENANTIOMERS OF ANALOGS OF THALIDOMIDE ALKYLATED IN 3-POSITION AND DETERMINATION OF THEIR ABSOLUTE-CONFIGURATION | 2 | 4 |
| 888 | 1 | 7 | 947 2000 BRITISH JOURNAL OF HAEMATOLOGY 108(2):391-393 Kneller A; Raanani P; Hardan I; Avigdor A; Levi I; Berkowicz M; Ben-Bassat I Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug | 53 | 75 |
| 889 | 0 | 12 | 400 1994 CHIRALITY 6(4):221-224 KNOCHE B; BLASCHKE G STEREOSELECTIVITY OF THE IN-VITRO METABOLISM OF THALIDOMIDE | 15 | 19 |
| 890 | 0 | 9 | 409 1994 JOURNAL OF CHROMATOGRAPHY A 666(1-2):235-240 KNOCHE B; BLASCHKE G INVESTIGATIONS ON THE IN-VITRO RACEMIZATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 20 | 31 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 891 | 0 | 0 | 1599 2003 BIOFUTUR (238):42-43 Knoll M The return of thalidomide | 0 | 0 |
| 892 | 1 | 8 | 68 1983 BRITISH JOURNAL OF DERMATOLOGY 108(4):461-466 KNOP J; BONSMANN G; HAPPLE R; LUDOLPH A; MATZ DR; MIFSUD EJ; MACHER E THALIDOMIDE IN THE TREATMENT OF 60 CASES OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 78 | 109 |
| 893 | 0 | 8 | 6 1981 ARCHIVES OF DERMATOLOGICAL RESEARCH 271(2):165-170 KNOP J; HAPPLE R; BONSMANN G; VAKILZADEH F; MACHER E TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 16 | 17 |
| 894 | 0 | 0 | 5 1981 ARCHIVES OF DERMATOLOGICAL RESEARCH 270(2):229-229 KNOP J; HAPPLE R; VAKILZADEH F; MACHER E TREATMENT OF LUPUS-ERYTHEMATOSUS PROFUNDUS WITH THALIDOMIDE | 11 | 13 |
| 895 | 2 | 12 | 88 1983 HAUTARZT 34(9):435-436 KNOP J; MACHER E THALIDOMIDE IN THE TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 4 | 4 |
| 896 | 0 | 0 | 768 1999 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
| 897 | 4 | 8 | 941 2000 BLOOD 96(12):3995-3996 Koc S; Leisenring W; Flowers MED; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ Thalidomide for treatment of patients with chronic graft-versus-host disease | 14 | 23 |
| 898 | 4 | 19 | 296 1990 TERATOLOGY 41(2):243-244 KOCH HP PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 2 | 4 |
| 899 | 1 | 17 | 201 1986 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 41(11-12):1057-1061 KOCH HP; CZEJKA MJ EVIDENCE FOR THE INTERCALATION OF THALIDOMIDE INTO DNA - CLUE TO THE MOLECULAR MECHANISM OF THALIDOMIDE TERATOGENICITY | 8 | 10 |
| 900 | 1 | 10 | 219 1988 ARCHIV DER PHARMAZIE 321(6):371-373 KOCH HP; STEINACKER C IMPROVEMENT OF SOLUBILITY AND STABILITY OF THALIDOMIDE BY INCLUSION COMPLEXATION WITH CYCLODEXTRINS | 2 | 4 |